Abciximab (CAT#: TP-100CL)

Figure 1 Anti-Human CD41 Recombinant Antibody (TP-100CL) in ELISA

ELISA analysis of TP-100CL was performed by coating with Human Integrin α2bβ3 (4 μg/mL). Abciximab TP-100CL were added with a series of dilutions (from 0 ng/mL to 5000 ng/mL). HRP-Rabbit Anti-Human IgG, F(ab')2 fragment antibody (1: 4000) were used to detect the bind Abciximab.

Figure 2 Anti-Human CD41 Recombinant Antibody (TP-100CL) in WB

Western blot analysis of TP-100CL was performed by loading Human Integrin α2bβ3.
TP-100CL incubation concentration: 4 ng/μL.
The secondary antibody: HRP-Goat-Anti-Human IgG (H+L)
Lane 1: Reducing antigen (2 μg)
Lane 2: Reducing antigen (4 μg)

Figure 3 Anti-Human CD41 Recombinant Antibody (TP-100CL) in DB

Dot blot analysis of TP-100CL was performed by loading Human Integrin α2bβ3.
TP-100CL incubation concentration: 4 ng/μL.
The secondary antibody: HRP-Goat-Anti-Human IgG (H+L)
NC: Negative control
PC: Positive control